{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:22:20Z","timestamp":1789762940650,"version":"4.0.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>Sinonasal squamous cell carcinoma (SNSCC) is sometimes associated with high-risk human papillomavirus (HR-HPV) infection and inverted sinonasal papilloma or oncocytic sinonasal papilloma. Frequent mutations of <jats:italic toggle=\"yes\">EGFR<\/jats:italic> and <jats:italic toggle=\"yes\">KRAS<\/jats:italic> are reported in inverted sinonasal papilloma\u2013related sinonasal squamous cell carcinoma (ISP-SCC) and oncocytic sinonasal papilloma\u2013related SNSCC, respectively. Here, we attempted to determine the prevalence and the prognostic significances of these alterations in SNSCC. We retrospectively collected 146 SNSCCs, including 14 ISP-SCCs, and comprehensively analyzed the HR-HPV infection by human papillomavirus (HPV)-RNA in situ hybridization, <jats:italic toggle=\"yes\">EGFR<\/jats:italic> gene copy number gain (CNG) by chromogenic in situ hybridization, and gene mutations in <jats:italic toggle=\"yes\">EGFR<\/jats:italic> and <jats:italic toggle=\"yes\">KRAS<\/jats:italic> by Sanger sequencing. HR-HPV was detected in 11 cases (7.5%), whereas all 14 ISP-SCCs were negative. <jats:italic toggle=\"yes\">EGFR<\/jats:italic> mutations were present in 21 (14.7%) of 143 SNSCCs, including 13\/14 (92.9%) ISP-SCCs and 8\/129 (6.2%) non\u2013ISP-SCCs (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001). The majority of <jats:italic toggle=\"yes\">EGFR<\/jats:italic> mutations were exon 20 insertions, with the remainder composed of deletions and single-nucleotide substitutions in exons 19 and 20. All of 142 SNSCCs harbored no <jats:italic toggle=\"yes\">KRAS<\/jats:italic> mutation. <jats:italic toggle=\"yes\">EGFR<\/jats:italic> CNG was detected in 41 (28.1%) of 146 SNSCCs; all of them were HPV negative and 3 had <jats:italic toggle=\"yes\">EGFR<\/jats:italic> mutations. Collectively, <jats:italic toggle=\"yes\">EGFR<\/jats:italic> mutation, <jats:italic toggle=\"yes\">EGFR<\/jats:italic> CNG, and HR-HPV were essentially mutually exclusive, and each subgroup had distinct clinicopathologic features. The HPV-negative\/<jats:italic toggle=\"yes\">EGFR<\/jats:italic>-mutant group, the HPV-negative\/<jats:italic toggle=\"yes\">EGFR<\/jats:italic> CNG-positive group, and the triple-negative group had significantly worse prognoses than the HPV-positive group (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.0265, 0.0264, and 0.0394, respectively). In conclusion, <jats:italic toggle=\"yes\">EGFR<\/jats:italic> mutation may play a pathogenetically important role in some populations of SNSCCs, especially ISP-SCCs. The molecular subclassification of SNSCCs may contribute to prognostic prediction and molecular-targeted precision medicine.<\/jats:p>","DOI":"10.1097\/pas.0000000000001566","type":"journal-article","created":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T18:07:21Z","timestamp":1598810841000},"page":"108-118","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":41,"title":["Clinicopathologic Significance of EGFR Mutation and HPV Infection in Sinonasal Squamous Cell Carcinoma"],"prefix":"10.1097","volume":"45","author":[{"given":"Takahiro","family":"Hongo","sequence":"first","affiliation":[{"name":"Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Jiromaru","sequence":"additional","affiliation":[{"name":"Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Nozaki","sequence":"additional","affiliation":[{"name":"Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Yasumatsu","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Yamaguchi Red Cross Hospital, Yamaguchi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Yoneda","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hamanomachi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Sugii","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneyuki","family":"Masuda","sequence":"additional","affiliation":[{"name":"Head and Neck Surgery, National Kyushu Cancer Center, Fukuoka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[{"name":"Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nrclinonc.2014.97","article-title":"Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances","volume":"11","author":"Llorente","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1002\/cncr.28108","article-title":"Paranasal sinus squamous cell carcinoma incidence and survival based on surveillance, epidemiology, and end results data, 1973 to 2009","volume":"119","author":"Ansa","year":"2013","journal-title":"Cancer"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/bjc.1987.303","article-title":"Tabacco use and sinonasal cancer: a case-control study","volume":"56","author":"Hayes","year":"1987","journal-title":"Br J Cancer"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12105-014-0527-7","article-title":"Carcinoma ex-Schneiderian papilloma (malignant transformation): a clinicopathologic and immunophenotypic study of 20 cases combined with a comprehensive review of the literature","volume":"8","author":"Nudell","year":"2014","journal-title":"Head Neck Pathol"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/PAS.0b013e3182698673","article-title":"Human papillomavirus-related carcinomas of the sinonasal tract","volume":"37","author":"Bishop","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/PAS.0000000000001410","article-title":"HPV-related sinonasal carcinoma: clinicopathologic features, diagnostic utility of p16 and Rb immunohistochemistry, and EGFR copy number alteration","volume":"44","author":"Jiromaru","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1007\/s00405-017-4571-2","article-title":"Malignant transformation of sinonasal inverted papilloma and related genetic alterations: a systematic review","volume":"274","author":"Re","year":"2017","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/PAS.0b013e318265fb2b","article-title":"Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6\/E7 mRNA in situ hybridization method","volume":"36","author":"Bishop","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1002\/cncr.24309","article-title":"Human papillomaviruses are identified in a subgroup of sinonasal squamous cell carcinomas with favorable outcome","volume":"115","author":"Alos","year":"2009","journal-title":"Cancer"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s12105-017-0779-0","article-title":"Transcriptionally active high-risk human papillomavirus is not a common etiologic agent in the malignant transformation of inverted Schneiderian papillomas","volume":"11","author":"Rooper","year":"2017","journal-title":"Head Neck Pathol"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/his.13868","article-title":"EGFR and KRAS mutations in Chinese patients with sinonasal inverted papilloma and oncocytic papilloma","volume":"75","author":"Wang","year":"2019","journal-title":"Histopathology"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00428-017-2116-0","article-title":"New tumor entities in the 4th edition of the World Health Organization classification of head and neck tumors: nasal cavity, paranasal sinuses and skull base","volume":"472","author":"Thompson","year":"2018","journal-title":"Virchows Arch"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/PAS.0000000000001411","article-title":"Transcriptionally active HPV and targetable EGFR mutations in sinonasal inverted papilloma: an association between low-risk HPV, condylomatous morphology, and cancer risk?","volume":"44","author":"Mehrad","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/annonc\/mdx736","article-title":"Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and associated sinonasal squamous cell carcinomas","volume":"29","author":"Udager","year":"2018","journal-title":"Ann Oncol"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/lary.23688","article-title":"Detection of human papillomavirus in sinonasal papillomas: systematic review and meta-analysis","volume":"123","author":"Syrj\u00e4nen","year":"2013","journal-title":"Laryngoscope"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1200\/JCO.2005.07.799","article-title":"Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions","volume":"23","author":"Pao","year":"2005","journal-title":"J Clin Oncol"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/cncr.26451","article-title":"Gene amplification and protein overexpression of EGFR and ERBB2 in sinonasal squamous cell carcinoma","volume":"118","author":"Lopez","year":"2012","journal-title":"Cancer"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/his.13732","article-title":"Sinonasal squamous cell carcinoma and EGFR mutations: a molecular footprint of a benign lesion","volume":"73","author":"Sasaki","year":"2018","journal-title":"Histopathology"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1158\/0008-5472.CAN-15-0340","article-title":"High-frequency targetable EGFR mutations in sinonasal squamous cell carcinomas arising from inverted sinonasal papilloma","volume":"75","author":"Udager","year":"2015","journal-title":"Cancer Res"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/path.4750","article-title":"Activating KRAS mutations are characteristic of oncocytic sinonasal papilloma and associated sinonasal squamous cell carcinoma","volume":"239","author":"Udager","year":"2016","journal-title":"J Pathol"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"12153","DOI":"10.3390\/ijms131012153","article-title":"Prognostic and predictive roles of KRAS mutation in colorectal cancer","volume":"13","author":"Arrington","year":"2012","journal-title":"Int J Mol Sci"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/CCO.0000000000000051","article-title":"The clinical relevance of KRAS gene mutation in non-small-cell lung cancer","volume":"26","author":"T\u00edm\u00e1r","year":"2014","journal-title":"Curr Opin Oncol"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"38789","DOI":"10.18632\/oncotarget.5887","article-title":"In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer","volume":"6","author":"Hirano","year":"2015","journal-title":"Oncotarget"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41591-018-0007-9","article-title":"Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer","volume":"24","author":"Robichaux","year":"2018","journal-title":"Nat Med"},{"key":"R27-20250608","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","article-title":"EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics","volume":"12","author":"Arcila","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"R31-20250608","doi-asserted-by":"crossref","first-page":"559","DOI":"10.5858\/arpa.2017-0286-CP","article-title":"Human papillomavirus testing in head and neck carcinomas: guideline from the College of American Pathologists","volume":"142","author":"Lewis","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R32-20250608","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.humpath.2015.11.001","article-title":"Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma","volume":"50","author":"Nakano","year":"2016","journal-title":"Hum Pathol"},{"key":"R33-20250608","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1126\/science.1208130","article-title":"The mutational landscape of head and neck squamous cell carcinoma","volume":"333","author":"Stransky","year":"2011","journal-title":"Science"},{"key":"R34-20250608","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nature14129","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","year":"2015","journal-title":"Nature"},{"key":"R35-20250608","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"R36-20250608","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"R37-20250608","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"R38-20250608","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1634\/theoncologist.2017-0069","article-title":"Multicenter phase II study of panitumumab in platinum pretreated, advanced head and neck squamous cell cancer","volume":"22","author":"Siano","year":"2017","journal-title":"Oncologist"},{"key":"R39-20250608","doi-asserted-by":"crossref","first-page":"9007","DOI":"10.1200\/JCO.2019.37.15_suppl.9007","article-title":"Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions","volume":"37","author":"Janne","year":"2019","journal-title":"J Clin Oncol"},{"key":"R40-20250608","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1158\/1535-7163.MCT-17-1206","article-title":"TAS6417, a novel EGFR inhibitor targeting exon 20 insertion mutations","volume":"17","author":"Hasako","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"R41-20250608","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T22:05:45Z","timestamp":1749420345000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001566","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,28]]}}}